The global rise in obesity and overweight individuals is a major public health concern, but addressing these conditions effectively remains challenging. Naltrexone, primarily known for treating opioid and alcohol dependence, has garnered attention for its potential role in weight management, particularly when combined with bupropion. This article explores the mechanisms by which naltrexone may contribute to weight loss, examines the evidence supporting its efficacy, and discusses the associated risks and considerations.
The Obesity Epidemic: A Growing Concern
Obesity is a chronic disease with increasing prevalence worldwide. The World Health Organization defines overweight as a body mass index (BMI) greater than 25 kg/m2 and obesity as a BMI greater than 30 kg/m2. These conditions result from excessive fat accumulation, leading to significant health hazards and chronic diseases. Overweight and obese individuals face a higher risk of comorbidities such as hypertension, diabetes mellitus, and cardiovascular disease, as well as increased mortality.
While lifestyle modifications can mitigate some of these risks, pharmacological interventions are sometimes considered. First- and second-generation antipsychotics, known to block 5HT2c serotonin receptors, can cause weight gain, highlighting the role of these receptors in appetite regulation. Even modest weight reduction can decrease obesity-related diseases and risk factors.
Bupropion and Naltrexone: A Combined Approach
Bupropion, a norepinephrine/dopamine-reuptake inhibitor (NDRI), was initially approved for treating depression in the 1990s. While some studies have linked bupropion to weight gain, others have reported weight loss or no significant change. Naltrexone, an opioid antagonist, is FDA-approved for treating alcohol use disorder. It is believed that opioid antagonists can block central opioid receptors, reducing the intake of certain foods. Naltrexone may reduce food consumption by blocking β-endorphin at the µ-opioid receptor.
The combined effect of bupropion and naltrexone on weight loss is thought to involve complementary mechanisms. Naltrexone may influence neurological pathways in the brain, while bupropion suppresses appetite. Clinical studies have shown that the bupropion/naltrexone combination can effectively promote weight loss in obese individuals compared to either medication alone.
Read also: Naltrexone: Dosage and Uses for Weight Loss
Mechanisms of Action
The precise mechanisms by which naltrexone/bupropion reduce weight are not fully understood. Pro-opiomelanocortin (POMC) neurons in the hypothalamus release α-melanocyte-stimulating hormone and β-endorphin. α-melanocyte-stimulating hormone regulates POMC activation, while β-endorphin activates opioid receptors on POMC neurons, causing autoinhibitory feedback. Bupropion monotherapy modestly increases POMC firing, leading to weight loss. The addition of naltrexone may prevent the β-endorphin-mediated autoinhibitory feedback loop, potentially sustaining weight reduction.
Clinical Evidence: Bupropion and Naltrexone in Weight Management
A systematic review and meta-analysis examined the effects of bupropion alone and in combination with naltrexone on weight, body mass index (BMI), and waist circumference (WC). The study adhered to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines. A comprehensive search was conducted in PubMed/MEDLINE, Web of Science, SCOPUS, and Embase databases up to February 2023, with no restrictions on language or time.
Search Strategy and Eligibility Criteria
The search included Medical Subject Headings (MeSH) and Emtree (Embase Subject Headings): (“Bupropion” OR " naltrexone " OR " Amfebutamone " OR " Wellbutrin " OR “Zyban " OR “Quomen” OR “Zyntabac “) AND (“weight” OR “Waist Circumference” OR “Body Mass Index”) AND (“Clinical Trials as Topic” OR “Cross-Over Studies” OR “Double-Blind Method” OR “Single-Blind Method” OR “Random Allocation” OR “Clinical Trial”). The reference lists of retrieved publications and review papers were manually examined to identify any overlooked trials.
Eligibility criteria included:
- Randomized clinical trial design.
- Administration of bupropion alone or combined with naltrexone to individuals aged 18 and older.
- Baseline and post-intervention measurements of weight, body mass index (BMI), and waist circumference (WC) for both intervention and control groups.
Studies with duplicated data, those specifically examining bupropion for smoking cessation, those with unclear information, studies using bupropion with other frequently prescribed medications (excluding naltrexone), non-randomized trials, animal studies, studies lacking a control group, and reviews/meta-analyses were excluded.
Read also: Naltrexone: Uses and Effectiveness
Data Extraction and Quality Assessment
Two researchers independently examined the qualifying studies, extracting data on the first author’s name, study location, publication year, sample size, participant characteristics (percentage of men, BMI, age, health status), outcomes assessed, intervention duration, dosage and type of intervention, and means and standard deviations (S.D.s) of outcomes at baseline and post-intervention.
The methodological quality of the included randomized controlled trials (RCTs) was assessed using version 2 of the Cochrane risk-of-bias tool for randomized trials (RoB 2). Potential sources of bias, including blinding of outcome assessment, allocation concealment, participant and staff blinding, random sequence generation, incomplete outcome data, selective reporting, and other bias, were evaluated. The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) grading technique was used to assess the quality of the analytic research.
Data Synthesis and Statistical Analysis
Data were analyzed using STATA version 12.0, and Endnote software facilitated the elimination of duplicate articles and the management of eligible articles. The random-effects model was used in the meta-analysis, with studies weighted according to the conventional inverse variance methodology. Heterogeneity was assessed using Q Statistics and I-squared (I2). Subgroup analysis was performed to ascertain potential factors contributing to heterogeneity, considering dosage, duration, and type of intervention. A sensitivity analysis was conducted to ascertain the individual contributions of each research study to the overall mean difference. Publication bias was assessed using Egger’s test.
Results of the Meta-Analysis
The meta-analysis included 25 publications with 33 treatment arms. The pooled findings showed that bupropion administration has an effect on lowering weight (WMD: -3.67 kg, 95% CI: -4.43 to -2.93) and WC (WMD: -2.98 cm, 95% CI -3.78 to -2.19) in compared with control groups. The analysis also showed that the effects of the present intervention on weight and WC during the intervention are > 26 weeks and ≤ 26 weeks compared to the other group, respectively.
Low-Dose Naltrexone (LDN): An Emerging Approach
Low-Dose Naltrexone (LDN), typically prescribed in doses of 0.5mg to 4.5mg, has been shown to have immune-modulating and anti-inflammatory properties with minimal side effects. Unlike traditional naltrexone dosing (50-100mg/day), LDN works by temporarily binding to opioid receptors, rather than fully blocking the opioid system. LDN also pairs well with GLP-1 agonists (e.g., Saxenda, Wegovy), particularly for patients with PCOS or leptin resistance.
Read also: Naltrexone for Weight Loss
Benefits and Side Effects
LDN is generally well tolerated, with mild and transient side effects. Many patients report improved sleep quality, which can further reduce inflammation, stabilize mood, and support metabolism. Providers often start at a low dose (0.5mg) and slowly titrate up to find the individual’s optimal dose.
Challenges and Considerations
LDN has flown under the radar due to its expired patent and low profit potential for pharmaceutical companies. Without corporate sponsorship, large-scale FDA trials are unlikely. It is crucial to obtain LDN from reputable compounding pharmacies to ensure the dose is tailored to individual conditions, lifestyle, and goals.
Risks and Side Effects of Naltrexone
While naltrexone and bupropion/naltrexone combinations have shown promise for weight loss, it is essential to consider the potential risks and side effects.
Common Side Effects
Common side effects of naltrexone use may include:
- Nausea and vomiting
- Dizziness
- Sleepiness
- Sleep disturbances
- Muscle cramps and joint pain
- Headache and toothache
- Flu-like symptoms
- Anxiety and irritability
- Constipation or diarrhea
Severe Adverse Effects
Severe adverse effects of taking Revia may include:
- Depression
- Hallucinations
- Pneumonia
- Confusion
- Blurred vision
- Dangerous allergic reaction, including swelling of mouth or tongue, chest pain, trouble breathing, and rash
- Hepatitis or liver damage, including dark-colored urine and jaundice
- Injection site reactions, including severe pain, tissue death, blisters, lumps, or open wounds
Overdose Risks
Naltrexone overdose is not common, with even high doses causing relatively benign symptoms. However, the real risk of naltrexone, aside from dangerous weight loss and disordered eating potential, is that of overdosing on opioids. Since naltrexone blocks opioid receptors, people taking this prescription medication are at risk of overdose if they relapse on heroin or a prescription opioid like Vicodin, Percocet, or other chronic pain management medications.
Eating Disorder Risks
Using a medication like naltrexone or naltrexone/bupropion to lose weight quickly could increase the risk of developing an eating disorder like bulimia nervosa or anorexia nervosa. Other symptoms of eating disorders include:
- Severe caloric restriction
- Skipping meals
- A preoccupation with food, weight, and thinness
- A pathological drive for thinness
- Distorted body image
- Low self-esteem
- Purging behaviors like laxative use, excessive exercise, and self-induced vomiting
- Binge eating episodes
- Feeling profound shame and guilt related to disordered eating behaviors
- Eating alone or avoiding situations in which food will be present
Naltrexone and Diet Culture
Naltrexone may be misused by people looking to lose weight thanks to diet culture, which prioritizes weight loss and thinness over health and well-being. Anti-fat bias, or fatphobia, is the intense hatred or fear of people living in larger bodies, and it contributes to the popularity of medications like naltrexone. Chronic disordered eating can ultimately lead to a clinical eating disorder, which may require formal eating disorder treatment.
tags: #naltrexone #50mg #for #weight #loss